NCT04629729 2026-03-19FT819 in Subjects With B-cell MalignanciesFate TherapeuticsPhase 1 Active not recruiting54 enrolled
NCT04023071 2023-10-26FT516 in Subjects With Advanced Hematologic MalignanciesFate TherapeuticsPhase 1 Terminated72 enrolled